Amgen's Stock Drops Despite Higher Price Target from Wells Fargo
Amgen's stock price dropped in response to Wells Fargo's latest research update. The upgrade, which included a higher price target, failed to shift sentiment towards a more bullish category.
The firm, while highlighting promising long-term demand for Repatha and Lipfendra, stuck with an Equal Weight rating, indicating no strong conviction that the stock will outperform. This mixed message may be weighing on investor sentiment in the near term.
Despite this volatility, Amgen's reliable free cash flow provides a powerful cushion, allowing the company to fund new drug research and maintain shareholder returns even through market fluctuations. However, concerns about the company's sizable debt load and rising costs may impact its flexibility if interest rates stay elevated or earnings growth slows.